The DOI matches its Crossref record.
Treatment of Toxic Epidermal Necrolysis with Cyclosporin A
Abstract
BACKGROUND: Toxic epidermal necrolysis (TEN) is a severe skin disorder characterized by separation of the dermal-epidermal junction, as is observed in second-degree superficial burns. It has been proposed that immunosuppressive treatment may improve prognosis of patients with TEN. METHODS: We report here a case series of patients with TEN treated with cyclosporin A (CSA) without other concomitant immunosuppressive agent. These patients (n = 11) were consecutively admitted to our Intensive Care Burn Unit because of severe TEN, involving a large body surface area (83 +/- 17% [mean +/- SD], median, 90%; range, 35-96%) and were treated with CSA 3 mg/kg per day enterally every 12 hours. We compared the series of patients treated with CSA with a historical series of patients admitted to our Intensive Care Burn Unit before CSA was introduced as part of the treatment protocol These patients (n = 6) were treated with cyclophosphamide (150 mg i.v. every 12 hours) and different doses of corticosteroids (> or =1 mg/kg per day of 6-methyl-prednisolone). Both groups of patients were similar in regard to age, delay from onset of disease to Intensive Care Burn Unit admission, and body surface area involved. RESULTS: Time from the onset of skin signs to arrest of the disease progression (1.4 +/- 0.3 days, vs. 3.6 +/- 1.5 days) and to complete reepithelialization (12.0 +/- 3.6 days, vs. 17.6 +/- 3.1 days) was significantly shorter in patients treated with CSA compared with those treated with cyclophosphamide and corticosteroids (p = 0.0002, and p = 0.0058, respectively). Significantly fewer patients in the CSA group had > or =4 organs failing (2 of 11 vs. 3 of 6, respectively, p = 0.029), had severe leukopenia (<1,000 cells/microL) (0 of 11 vs. 4 of 6, respectively, p = 0.006), or died (3 of 6 vs. 0 of 11, respectively, p = 0.0029). CONCLUSION: We conclude that immunosuppressive treatment with CSA is safe and is associated with a rapid reepithelialization rate and a low mortality rate in patients with severe TEN. Our data suggest that this regimen could be more effective than treatment with cyclophosphamide and corticosteroids. Prospective controlled trials are required to test the hypothesis that CSA is more effective than cyclophosphamide or other immunosuppressive regimens for the treatment of TEN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Toxic epidermal necrolysis and Stevens-Johnson syndrome
Harr, T., & French, L. E. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-39 · Cited by 693
Pereira, F. A., Mudgil, A. V., & Rosmarin, D. M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.048 · Cited by 376
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Lerch, M., Mainetti, C., Terziroli Beretta-Piccoli, B., & Harr, T. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8654-z · Cited by 355
Schwartz, R. A., McDonough, P. H., & Lee, B. W. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.05.002 · Cited by 338
Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., et al. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.26 · Cited by 325
Metadata
- Authors
- Ar??valo, J. M., Lorente, J. A., Gonz??lez-Herrada, C., & Jim??nez-Reyes, J.
- Venue
- The Journal of Trauma: Injury, Infection, and Critical Care
- Published
- 2000-03
- Volume
- 48
- Issue
- 3
- Pages
- 473-478
- ISSN
- 0022-5282 (ISSN-L)
- OpenAlex
- W1506187427
- Cited by
- 212
- References
- 0
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Toxic Epidermal Necrolysis with Cyclosporin A. https://app.cochat.ai/papers/10.1097/00005373-200003000-00017
- The paper
- Ar??valo, J. M., Lorente, J. A., Gonz??lez-Herrada, C., & Jim??nez-Reyes, J. (2000). Treatment of Toxic Epidermal Necrolysis with Cyclosporin A. The Journal of Trauma: Injury, Infection, and Critical Care. https://doi.org/10.1097/00005373-200003000-00017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.